ALNY Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of -22.27% compared to Alnylam Pharmaceuticals's net margin of 16.61%. Alnylam Pharmaceuticals's return on equity of -- beat Gilead Sciences's return on equity of 0.64%.

Alnylam Pharmaceuticals has a consensus price target of $299.11, signalling upside risk potential of 21.84%. On the other hand Gilead Sciences has an analysts' consensus of $98.92 which suggests that it could grow by 6.86%. Given that Alnylam Pharmaceuticals has higher upside potential than Gilead Sciences, analysts believe Alnylam Pharmaceuticals is more attractive than Gilead Sciences.

Alnylam Pharmaceuticals has a beta of 0.319, which suggesting that the stock is 68.077% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.175, suggesting its less volatile than the S&P 500 by 82.499%.

Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 3.33% to investors and pays a quarterly dividend of $0.77 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. Gilead Sciences pays out 67.24% of its earnings as a dividend. Gilead Sciences's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Alnylam Pharmaceuticals quarterly revenues are $500.9M, which are smaller than Gilead Sciences quarterly revenues of $7.5B. Alnylam Pharmaceuticals's net income of -$111.6M is lower than Gilead Sciences's net income of $1.3B. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 1,028.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 14.86x versus 4.09x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -22.27% compared to Alnylam Pharmaceuticals's net margin of 25.23%. Alnylam Pharmaceuticals's return on equity of -- beat Pfizer's return on equity of 4.63%.

Alnylam Pharmaceuticals has a consensus price target of $299.11, signalling upside risk potential of 21.84%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 20.88%. Given that Alnylam Pharmaceuticals has higher upside potential than Pfizer, analysts believe Alnylam Pharmaceuticals is more attractive than Pfizer.

Alnylam Pharmaceuticals has a beta of 0.319, which suggesting that the stock is 68.077% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.37% to investors and pays a quarterly dividend of $0.42 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Alnylam Pharmaceuticals quarterly revenues are $500.9M, which are smaller than Pfizer quarterly revenues of $17.7B. Alnylam Pharmaceuticals's net income of -$111.6M is lower than Pfizer's net income of $4.5B. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while Pfizer's PE ratio is 35.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 14.86x versus 2.52x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -22.27% compared to Alnylam Pharmaceuticals's net margin of 36.03%. Alnylam Pharmaceuticals's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Alnylam Pharmaceuticals has a consensus price target of $299.11, signalling upside risk potential of 21.84%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,053.08 which suggests that it could grow by 50.04%. Given that Regeneron Pharmaceuticals has higher upside potential than Alnylam Pharmaceuticals, analysts believe Regeneron Pharmaceuticals is more attractive than Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals has a beta of 0.319, which suggesting that the stock is 68.077% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.084, suggesting its less volatile than the S&P 500 by 91.622%.

Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Alnylam Pharmaceuticals quarterly revenues are $500.9M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Alnylam Pharmaceuticals's net income of -$111.6M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 14.86x versus 5.83x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -22.27% compared to Alnylam Pharmaceuticals's net margin of 7.2%. Alnylam Pharmaceuticals's return on equity of -- beat Sarepta Therapeutics's return on equity of 12.48%.

Alnylam Pharmaceuticals has a consensus price target of $299.11, signalling upside risk potential of 21.84%. On the other hand Sarepta Therapeutics has an analysts' consensus of $185.10 which suggests that it could grow by 55.59%. Given that Sarepta Therapeutics has higher upside potential than Alnylam Pharmaceuticals, analysts believe Sarepta Therapeutics is more attractive than Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals has a beta of 0.319, which suggesting that the stock is 68.077% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.767, suggesting its less volatile than the S&P 500 by 23.328%.

Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Alnylam Pharmaceuticals quarterly revenues are $500.9M, which are larger than Sarepta Therapeutics quarterly revenues of $467.2M. Alnylam Pharmaceuticals's net income of -$111.6M is lower than Sarepta Therapeutics's net income of $33.6M. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 77.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 14.86x versus 7.30x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.